Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)

ASH Tsai, HD Chou, XC Ling, T Al-Khaled… - Progress in retinal and …, 2022 - Elsevier
The incidence of retinopathy of prematurity (ROP) continues to rise due to the improved
survival of very low birth weight infants in developed countries. This epidemic is also fueled …

Neurodevelopmental outcomes after bevacizumab treatment for retinopathy of prematurity: a meta-analysis

CY Tsai, PT Yeh, PN Tsao, YCE Chung, YS Chang… - Ophthalmology, 2021 - Elsevier
Purpose To evaluate neurodevelopmental outcomes after intravitreal bevacizumab (IVB)
therapy in retinopathy of prematurity (ROP) infants compared with those not exposed to IVB …

Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity

KA Kennedy, HA Mintz-Hittner… - Journal of American …, 2018 - Elsevier
Background Infants with stage 3+ retinopathy of prematurity (ROP) in zone I or zone II
posterior were randomized to initial treatment with bevacizumab or laser in a multicenter trial …

Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study

YY Fan, YS Huang, CY Huang, JF Hsu, CP Shih… - Ophthalmology, 2019 - Elsevier
Purpose To evaluate the neurodevelopmental and ocular developmental outcomes in
premature children who have undergone intravitreal bevacizumab injection (IVB) for …

Laser versus anti-VEGF: a paradigm shift for treatment-warranted retinopathy of prematurity

ME Hartnett, A Stahl - Ophthalmology and Therapy, 2023 - Springer
Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically
been associated with blindness from overgrowth of blood vessels from the retina into the …

Early vitamin A supplementation improves the outcome of retinopathy of prematurity in extremely preterm infants

H Sun, R Cheng, Z Wang - Retina, 2020 - journals.lww.com
Purpose: This study assessed the efficacy and safety of early vitamin A (VA)
supplementation to improve outcomes of retinopathy of prematurity in extremely preterm …

Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal Anti–Vascular endothelial growth factor

GP Barry, Y Yu, GS Ying, LA Tomlinson, J Lajoie… - Ophthalmology, 2021 - Elsevier
Purpose To compare rates of short-term retinal detachment (RD) of infants treated for type 1
retinopathy of prematurity (ROP) with intravitreal anti–vascular endothelial growth factor …

Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP

SH Rodriguez, C Peyton, K Lewis… - … Surgery, Lasers and …, 2019 - journals.healio.com
BACKGROUND AND OBJECTIVE: To evaluate neurodevelopmental outcomes among
infants treated for retinopathy of prematurity (ROP) at the authors' institution. PATIENTS AND …

Neurodevelopmental outcomes for retinopathy of prematurity: a Taiwan premature infant follow-up network database study

MC Chiang, YT Chen, EYC Kang, KJ Chen… - American Journal of …, 2023 - Elsevier
PURPOSE To evaluate the neurodevelopmental outcomes in premature infants who
received intravitreal anti− vascular endothelial growth factor (anti-VEGF) injections to treat …

Update on the use of anti-VEGF drugs in the treatment of retinopathy of prematurity

CW Seery, S Betesh, S Guo, MA Zarbin… - Journal of Pediatric …, 2020 - journals.healio.com
Retinopathy of prematurity (ROP) is one of the many significant consequences of premature
birth and remains one of the leading causes of visual impairment in infants. Originally …